Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
SQZ Biotechnologies Company SQZ
$0.62
+$0.02 (3.33%)
На 18:03, 12 мая 2023
+545.16%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
18726849.00000000
-
week52high
4.02
-
week52low
0.53
-
Revenue
-449000
-
P/E TTM
-1
-
Beta
2.69033500
-
EPS
-2.60000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 25 мая 2022 г. | |
| Evercore ISI Group | Outperform | 08 янв 2021 г. | |
| Stifel | Buy | 24 ноя 2020 г. | |
| BTIG | Buy | 24 ноя 2020 г. | |
| B of A Securities | Buy | 24 ноя 2020 г. | |
| BTIG | Buy | Buy | 06 окт 2022 г. |
| HC Wainwright & Co. | Buy | 20 окт 2022 г. | |
| Chardan Capital | Buy | Buy | 10 ноя 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 02 дек 2022 г. |
| Chardan Capital | Buy | Buy | 01 дек 2022 г. |
| B of A Securities | Underperform | Buy | 01 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Capasso Richard | A | 213000 | 213000 | 24 янв 2023 г. |
| First David | A | 200000 | 200000 | 24 янв 2023 г. |
| Knopf Lawrence J | A | 227000 | 227000 | 24 янв 2023 г. |
| Warren Marshelle Smith | A | 261000 | 261000 | 24 янв 2023 г. |
| BERNSTEIN HOWARD PHD MD | A | 830000 | 830000 | 24 янв 2023 г. |
| Capasso Richard | D | 0 | 1183 | 15 авг 2022 г. |
| Zajic Micah | A | 10000 | 10000 | 11 июл 2022 г. |
| Capasso Richard | A | 1183 | 1183 | 30 июн 2022 г. |
| Knopf Lawrence J | A | 1938 | 1484 | 30 июн 2022 г. |
| Sharei Armon | A | 287884 | 2436 | 30 июн 2022 г. |
Новостная лента
SQZ Biotechnologies to Present at Upcoming Investor Conferences
Business Wire
07 сент 2022 г. в 16:30
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 and at the Chardan 6th Annual Genetic Medicines Conference on October 4. Both conference presentations will be held in New York, NY. Prese
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Seeking Alpha
08 июн 2022 г. в 14:30
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
Business Wire
01 июн 2022 г. в 16:45
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on June 8, in New York, NY. Presentation time and webcast information is available below. PRESENTATION DETAILS Wednesday, June 8 Jefferies Healthcare Conference 2:30-2:55 p.m. ET Webcast
SQZ Biotechnologies to Present at Upcoming Investor Conferences
Business Wire
06 апр 2022 г. в 16:45
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, and Chardan's 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26. Presentation times and webcast information are available bel